Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viela Bio, Inc.

https://vielabio.com

Latest From Viela Bio, Inc.

Stock Watch: Why Have Biotech Acquisitions Paused?

The subdued number of acquisitions of biotech by big pharma has more than one cause. The structural improvement of the process of drug discovery and development at big pharma is the main one.

M & A Stock Watch

Finance Watch: US, Hong Kong IPOs Are Hot, But Sirnaomics Stays Private

Private Company Edition: Sirnaomics planned to go public after its series D, but its new venture capital does not prevent it from doing so in the near term. Also, Vida Ventures and Novalis Biotech raised new VC funds to back start-ups and ArriVent launched with up to $150m in series A cash.

Financing Innovation

Lengthy EU Regulatory Review Ends Well For Roche’s NMOSD Therapy

The European Medicines Agency has finally recommended pan-EU marketing approval for Roche’s Enspryng.

Europe Neurology

With Return Of Tepezza Supply, Horizon Is Ready To Get Back To Business

US FDA approved new manufacturing for Tepezza, which had been sidelined by COVID-19 vaccine production. Horizon said it will resupply the market in April.

Business Strategies Launches
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register